P
Paul A. Sobotka
Researcher at University of Minnesota
Publications - 18
Citations - 736
Paul A. Sobotka is an academic researcher from University of Minnesota. The author has contributed to research in topics: Blood pressure & Denervation. The author has an hindex of 9, co-authored 18 publications receiving 703 citations.
Papers
More filters
Journal ArticleDOI
Renal Denervation in Moderate to Severe CKD
Dagmara Hering,Felix Mahfoud,Antony Walton,Henry Krum,Gavin Lambert,Elisabeth Lambert,Paul A. Sobotka,Michael Böhm,Bodo Cremers,Murray D. Esler,Murray D. Esler,Markus P. Schlaich,Markus P. Schlaich +12 more
TL;DR: A favorable short-term safety profile and beneficial BP effects of catheter-based renal nerve ablation in patients with stage 3-4 CKD and resistant hypertension are suggested.
Journal ArticleDOI
Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease.
Markus P. Schlaich,Markus P. Schlaich,Markus P. Schlaich,Bradley A. Bart,Dagmara Hering,Dagmara Hering,Antony Walton,Petra Marusic,Felix Mahfoud,Michael Böhm,Elisabeth Lambert,Elisabeth Lambert,Henry Krum,Paul A. Sobotka,Roland E. Schmieder,Carolina Ika-Sari,Nina Eikelis,Nora E. Straznicky,Gavin W. Lambert,Gavin W. Lambert,Murray D. Esler +20 more
TL;DR: RDN is feasible in patients with ESRD and associated with a sustained reduction in systolic office BP, and atrophic renal arteries may pose a problem for application of this technology in some patients withESRD.
Journal ArticleDOI
Effects of Renal Denervation on Sympathetic Activation, Blood Pressure, and Glucose Metabolism in Patients with Resistant Hypertension
Markus P. Schlaich,Dagmara Hering,Paul A. Sobotka,Henry Krum,Gavin W. Lambert,Elisabeth Lambert,Murray D. Esler +6 more
TL;DR: Initial data from two clinical trials and several smaller mechanistic clinical studies indicate that this novel approach may indeed provide a safe and effective treatment alternative for resistant hypertension and some of its adverse consequences.
Journal ArticleDOI
Renal nerve ablation reduces augmentation index in patients with resistant hypertension.
Dagmara Hering,Elisabeth Lambert,Elisabeth Lambert,Petra Marusic,Carolina Ika-Sari,Antony Walton,Henry Krum,Paul A. Sobotka,Felix Mahfoud,Michael Böhm,Gavin W. Lambert,Gavin W. Lambert,Murray D. Esler,Murray D. Esler,Markus P. Schlaich,Markus P. Schlaich +15 more
TL;DR: RDN results in a substantial and rapid reduction in augmentation index, which appears to be independent of BP and MSNA changes, and is indicative of a beneficial effect of RDN on arterial stiffness in patients with resistant hypertension.
Journal ArticleDOI
The sympathorenal axis in hypertension and heart failure.
TL;DR: Should their early promise be borne out in controlled studies, the "sympathorenal axis" will have been proven to be a key element in the pathophysiology of these 2 very common, and dangerous, conditions.